1. Home
  2. BTBD vs LNAI Comparison

BTBD vs LNAI Comparison

Compare BTBD & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

N/A

Current Price

$1.75

Market Cap

11.4M

ML Signal

N/A

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$1.42

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTBD
LNAI
Founded
1987
N/A
Country
United States
United States
Employees
188
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4M
12.4M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
BTBD
LNAI
Price
$1.75
$1.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.2K
★ 36.4K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $14,823,472.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.15
52 Week High
$2.48
$5.02

Technical Indicators

Market Signals
Indicator
BTBD
LNAI
Relative Strength Index (RSI) 64.48 25.99
Support Level $1.10 $0.26
Resistance Level $1.93 $2.58
Average True Range (ATR) 0.13 0.25
MACD -0.01 -0.08
Stochastic Oscillator 77.27 7.39

Price Performance

Historical Comparison
BTBD
LNAI

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: